Source: Health Products Regulatory Authority (IE) Revision Year: 2019 Publisher: Sanofi-Aventis Ireland Limited T/A SANOFI, Citywest Business Campus, Dublin 24, Ireland
Surmontil 25mg film-coated Tablets.
| Pharmaceutical Form |
|---|
|
Film-coated tablet. White to pale yellow, circular, biconvex, film-coated tablet, one face impressed “SURMONTIL” just inside the perimeter around a centrally impressed ‘25’, reverse face plain. |
Each tablet contains Trimipramine Maleate equivalent to 25 mg of Trimipramine.
Excipients: each tablet contains 4.32 mg lactose monohydrate.
For a full list of excipients, see section 6.1.
| List of Excipients |
|---|
|
Starch potato |
Surmontil 25 mg tablets are marketed in Grey 50 ml High density polyethylene (h.d.p.e.) bottles. Each bottle contains 50 tablets.
Sanofi-Aventis Ireland Limited T/A SANOFI, Citywest Business Campus, Dublin 24, Ireland
PA0540/128/005
Date of first authorisation: 01 April 1978
Date of last renewal 05 October 2010
| Drug | Countries | |
|---|---|---|
| SURMONTIL | Spain, Finland, France, Hong Kong, Ireland, Japan, Tunisia |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
